Current Alzheimer Research

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back Subscribe
Editorial

Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies

Author(s): Shampa Ghosh and Jitendra Kumar Sinha

Volume 22, Issue 9, 2025

Published on: 03 October, 2025

Page: [631 - 633] Pages: 3

DOI: 10.2174/0115672050443568250926174642

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor
Next »
[1]
Algantri KR, Hamzah M, Nasir M, Rahman A. Neuroprotective agents: Implications for parkinson’s disease treatment. Curr Alzheimer Res 2025; 22: 634-60.
[http://dx.doi.org/10.2174/0115672050368080250529075006]
[2]
Chauhan BS, Singh YP, Poeggeler B, Singh SK. Therapeutic Advances in Alzheimer’s Disease: Integrating natural, semi-synthetic, and synthetic drug strategies. Curr Alzheimer Res 2025; 22: 1-17.
[http://dx.doi.org/10.2174/0115672050366727250513061730] [PMID: 40454492]
[3]
Bhaskar R, Narayanan KB, Singh KK, Han SS. Mapping the connection between circadian rhythms, metabolism, and neurodegeneration: Exploring therapeutic strategies. Curr Alzheimer Res 2025; 22: 678-97.
[http://dx.doi.org/10.2174/0115672050381989250626071304]
[4]
Singh A, Sethi P, Ghosh S. Current status of prevention strategies adapted for Alzheimer’s disease.In: A New Era in Alzheimer’s Research: Pathogenesis, Prevention, and Treatment. United States: Academic Press 2024.
[http://dx.doi.org/10.1016/B978-0-443-15540-6.00004-5]
[5]
Mishra PK, Ghosh S, Singh KK, Sinha JK. Physical exercise and lifestyle management: Preventive measures for Alzheimer’s disease.In: A New Era in Alzheimer’s Research: Pathogenesis, Prevention, and Treatment. United States: Academic Press 2024.
[http://dx.doi.org/10.1016/B978-0-443-15540-6.00003-3]
[6]
Sachdeva P, Narayanan KB, Sinha JK, et al. Recent advances in drug delivery systems targeting insulin signalling for the treatment of Alzheimer’s Disease. J Alzheimers Dis 2024; 98(4): 1169-79.
[http://dx.doi.org/10.3233/JAD-231181] [PMID: 38607755]
[7]
Vashisth K, Sharma S, Ghosh S, et al. Immunotherapy in Alzheimer’s Disease: Current status and future directions. J Alzheimers Dis 2024; 101(s1): S23-39.
[http://dx.doi.org/10.3233/JAD-230603] [PMID: 39422934]
[8]
Bano S, Raza MA, Ghosh S. Emerging therapeutic targets in molecular neuropharmacology for Alzheimer’s Disease. J Biol Regul Homeost Agents 2023; 37(11): 5769-84.
[http://dx.doi.org/10.23812/j.biol.regul.homeost.agents.20233711.553]
[9]
Ghosh S, Sachdeva B, Sachdeva P, Chaudhary V, Rani GM, Sinha JK. Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease. Carbon Letters 2022; 32(6): 1381-94.
[http://dx.doi.org/10.1007/s42823-022-00397-9]
[10]
Mishra P, Mittal AK, Kalonia H, et al. SIRT1 promotes neuronal fortification in neurodegenerative diseases through attenuation of pathological hallmarks and enhancement of cellular lifespan. Curr Neuropharmacol 2021; 19(7): 1019-37.
[http://dx.doi.org/10.2174/1570159X18666200729111744] [PMID: 32727328]
[11]
Sethi P, Bhaskar R, Singh KK, et al. Exploring advancements in early detection of Alzheimer’s disease with molecular assays and animal models. Ageing Res Rev 2024; 100: 102411.
[http://dx.doi.org/10.1016/j.arr.2024.102411] [PMID: 38986845]
[12]
Sethi P, Singh KK, Amist AD. Molecular and neuroimaging biomarkers in the diagnosis of Alzheimer’s Disease.In: A New Era in Alzheimer’s Research: Pathogenesis, Prevention, and Treatment. United States: Academic Press 2024.
[http://dx.doi.org/10.1016/B978-0-443-15540-6.00006-9]
[13]
Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK. Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer’s Disease. Curr Neuropharmacol 2020; 18(9): 883-903.
[http://dx.doi.org/10.2174/1570159X18666200429011823] [PMID: 32348223]

Rights & Permissions Print Cite